专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明授权

US07807640B2 Orally administered peptides synergize statin activity 失效
标题翻译：口服施用的肽协同他汀类活性
公开(公告)号：US07807640B2
公开(公告)日：2010-10-05
申请号：US11689037
申请日：2007-03-21
申请人： Alan M. Fogelman , Gattadahalli M. Anantharamaiah , Mohamad Navab
发明人： Alan M. Fogelman , Gattadahalli M. Anantharamaiah , Mohamad Navab
IPC分类号： A61K38/16
CPC分类号： C07K7/08 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/405 , A61K31/44 , A61K31/47 , A61K31/505 , A61K38/10 , A61K38/16 , C07K14/001 , C07K14/775 , Y02P20/55 , A61K2300/00
摘要： This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are class A amphipathic helical peptides. They are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention also provides a method of tracking a peptide in a mammal. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more anti-inflammatory at any given dose.
摘要翻译：本发明提供改善一种或多种动脉粥样硬化症状的新型肽。肽是A类两亲性螺旋肽。它们是高度稳定的，并且通过口服途径容易地施用。这些肽有效地刺激pre-β高密度脂蛋白样颗粒的形成和循环和/或促进脂质运输和解毒。本发明还提供了一种跟踪哺乳动物中的肽的方法。此外，肽抑制骨质疏松症。当与他汀类药物一起使用时，肽增强了他汀类药物的活性，允许以显着较低的剂量使用他汀类药物，和/或使得他汀类药物在任何给定剂量下显着更具抗炎作用。

22. 发明授权

US07723303B2 Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response 有权
标题翻译：肽和肽模拟物，用于治疗以炎症反应为特征的病态
公开(公告)号：US07723303B2
公开(公告)日：2010-05-25
申请号：US11407390
申请日：2006-04-18
申请人： Alan M. Fogelman , Mohamad Navab , Gattadahalli M. Anantharamaiah
发明人： Alan M. Fogelman , Mohamad Navab , Gattadahalli M. Anantharamaiah
IPC分类号： A61F2/82 , A61K38/10 , C07K7/08
CPC分类号： A61L31/16 , A61K38/00 , A61L2300/25 , A61L2300/40 , C07K7/08 , C07K14/775
摘要： This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route.
摘要翻译：本发明提供改善一种或多种动脉粥样硬化症状的新型活性剂（例如肽，小有机分子，氨基酸对等）肽和/或以炎症反应为特征的其它病症。在某些实施方案中，肽类似于载脂蛋白J的G *两亲性螺旋。这些试剂是高度稳定的并且通过口服途径容易地施用。

23. 发明授权

US07144862B2 Orally administered peptides to ameliorate atherosclerosis 有权
标题翻译：口服给药以改善动脉粥样硬化
公开(公告)号：US07144862B2
公开(公告)日：2006-12-05
申请号：US10187215
申请日：2002-06-28
申请人： Alan M. Fogelman , Gattadahalli M. Anantharamaiah , Mohamad Navab
发明人： Alan M. Fogelman , Gattadahalli M. Anantharamaiah , Mohamad Navab
IPC分类号： A61K38/10 , C07K7/08
CPC分类号： C07K14/775 , A61K38/00 , Y02P20/55
摘要： This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. In certain embodiments, the peptide comprises an amino acid sequence that ranges in length from about 10 up to about 30 amino acids, that comprises at least one class A amphipathic helix, that bears at least one protecting group, that protects a phospholipid against oxidation by an oxidizing agent; and that is not the D-18A peptide. The peptides are highly stable and readily administered via an oral route.
摘要翻译：本发明提供改善一种或多种动脉粥样硬化症状的新型肽。在某些实施方案中，肽包含长度为约10至约30个氨基酸的氨基酸序列，其包含至少一个A类两亲性螺旋，其具有至少一个保护基团，其保护磷脂免受氧化氧化剂; 而不是D-18A肽。肽通过口服途径高度稳定并容易地施用。

24. 发明授权

US06664230B1 Orally administered peptides to ameliorate atherosclerosis 有权
标题翻译：口服给药以改善动脉粥样硬化
公开(公告)号：US06664230B1
公开(公告)日：2003-12-16
申请号：US09645454
申请日：2000-08-24
申请人： Alan M. Fogelman , Gattadahalli M. Anantharamaiah , Mohamad Navab
发明人： Alan M. Fogelman , Gattadahalli M. Anantharamaiah , Mohamad Navab
IPC分类号： A61K3808
CPC分类号： C07K14/775 , A61K38/00 , Y02P20/55
摘要： This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route.
摘要翻译：本发明提供改善一种或多种动脉粥样硬化症状的新型肽。肽通过口服途径高度稳定并容易地施用。

25. 发明授权

US6156727A Anti-atherosclerotic peptides and a transgenic mouse model of antherosclerosis 失效
标题翻译：抗动脉粥样硬化肽和转基因小鼠模型的动脉粥样硬化
公开(公告)号：US6156727A
公开(公告)日：2000-12-05
申请号：US924280
申请日：1997-09-05
申请人： David W. Garber , Gattadahalli M. Anantharamaiah
发明人： David W. Garber , Gattadahalli M. Anantharamaiah
IPC分类号： A61K38/00 , C07K14/775 , C07K5/00
CPC分类号： C07K14/775 , A01K2217/05 , A61K38/00
摘要： The present invention provides an anti-atherosclerotic peptide, said peptide being an amphipathic helical peptide compared with human apoA-I, characterized by having at least 4 of the following 8 properties: a tandem repeating class A amphipathic helix linked by a proline which forms an optimal arrangement for lipid association, has bilayer membrane stabilizing properties, stimulates HIV-I Gp41-induced cell fusion, stimulates neutrophil activation, stimulates BSA-induced lysis of fatty acid-containing vesicles, stimulates human placental lactogen synthesis, effluxes phospholipid and cellular cholesterol from cholesterol-loaded cells, and competes with HDL for binding to cells. The present invention is also directed to pharmaceutical compositions, transgenic animals expressing a protein disclosed herein, vectors expressing such proteins.
摘要翻译：本发明提供抗动脉粥样硬化肽，所述肽与人apoA-I相比是两亲性螺旋肽，其特征在于具有以下8种特性中的至少4种：由脯氨酸连接的串联重复类A两亲性螺旋，其形成脂质结合的最佳布置，具有双层膜稳定性质，刺激HIV-I Gp41诱导的细胞融合，刺激嗜中性粒细胞活化，刺激BSA诱导的含脂肪酸囊泡的裂解，刺激人胎盘乳糖合成，排出磷脂和细胞胆固醇胆固醇负载细胞，并与HDL竞争结合细胞。本发明还涉及药物组合物，表达本文公开的蛋白质的转基因动物，表达这种蛋白质的载体。

26. 发明授权

US4643988A Amphipathic peptides 失效
标题翻译：两亲肽
公开(公告)号：US4643988A
公开(公告)日：1987-02-17
申请号：US610444
申请日：1984-05-15
申请人： Jere P. Segrest , Gattadahalli M. Anantharamaiah
发明人： Jere P. Segrest , Gattadahalli M. Anantharamaiah
IPC分类号： C07K7/08 , A61K9/00 , A61K38/00 , A61K47/24 , A61P3/06 , C07K14/00 , C07K14/775 , A61K37/43 , C07K7/10
CPC分类号： C07K14/775 , A61K38/00
摘要： The present invention relates to peptides of the formulaA.sub.1 -B.sub.1 -B.sub.2 -C.sub.1 -D-B.sub.3 -B.sub.4 -A.sub.2 -C.sub.2 -B.sub.5 -B.sub.6 -A.sub.3 -C.sub.3 -B.sub.7 -C.sub.4 -A.sub.4 -B.sub.8 -B.sub.9wherein:A.sub.1, A.sub.2, A.sub.3 and A.sub.4 are independently aspartic acid or glutamic acid, or homologues or analogues thereof;B.sub.1, B.sub.2, B.sub.3, B.sub.4, B.sub.5, B.sub.6, B.sub.7, B.sub.8 and B.sub.9 are independently tryptophan, phenylalanine, leucine, alanine, tyrosine, isoleucine, valine or .alpha.-naphtylalanine, or homologues or analogues thereof; C.sub.1, C.sub.2, C.sub.3, and C.sub.4 are independently lysine or arginine, or homologues or analogues thereof, and D is serine, threonine, alanine, glycine, or histidine; provided that, when A.sub.1 and A.sub.2 are aspartic acid, A.sub.3 and A.sub.4 are glutamic acid, B.sub.2 and B.sub.7 are leucine, B.sub.3 and B.sub.9 are phenylalanine, B.sub.4 is tyrosine, B.sub.5 is valine, and C.sub.1, C.sub.2, C.sub.3 and C.sub.4 are lysine, and B.sub.6, B.sub.8 and D are alanine, B.sub.1 is not tryptophan. These peptides are useful in the treatment and prevention of atherosclerosis.
摘要翻译：本发明涉及式A1-B1-B2-C1-D-B3-B4-A2-C2-B5-B6-A3-C3-B7-C4-A4-B8-B9的肽，其中：A1，A2， A3和A4独立地是天冬氨酸或谷氨酸，或其同系物或类似物; B1，B2，B3，B4，B5，B6，B7，B8和B9独立地是色氨酸，苯丙氨酸，亮氨酸，丙氨酸，酪氨酸，异亮氨酸，缬氨酸或α-萘基丙氨酸或其同系物或类似物; C1，C2，C3和C4独立地是赖氨酸或精氨酸，或其同系物或类似物，D是丝氨酸，苏氨酸，丙氨酸，甘氨酸或组氨酸; 条件是当A1和A2为天冬氨酸时，A3和A4为谷氨酸，B2和B7为亮氨酸，B3和B9为苯丙氨酸，B4为酪氨酸，B5为缬氨酸，C1，C2，C3和C4为赖氨酸， B6，B8和D是丙氨酸，B1不是色氨酸。这些肽可用于治疗和预防动脉粥样硬化。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式